RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1704, Issue 2, 2004, Pages 49-57

  Wittrant, Y ^a   Theoleyre S ^a   Chipoy, C ^a   Padrines, M ^a   Blanchard, F ^a   Heymann, D ^a   Redini F ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

OPG; RANK; Tumour

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN; RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B PROTEIN; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

BONE CANCER; BONE CELL; BONE DESTRUCTION; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; BONE TUMOR; BREAST CARCINOMA; CANCER MODEL; CANCER PATIENT; CELL ACTIVATION; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG UTILIZATION; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOCLASTOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLUBILITY; STANDARD; STROMA CELL; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 4444257291     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2004.05.002     Document Type: Review

References (67)

1. Weber M.H., Goltzman D., Kostenuik P., Rabbani S., Singh G., Duivenvoorden W.C., Orr F.W. Mechanisms of tumor metastasis to bone. Crit. Rev. Eukaryot. Gene Expr. 10:2000;281-302
2. Eilon G., Mundy G.R. Direct resorption of bone by human breast cancer cells in vitro. Nature. 276:1978;726-728
3. Guise T.A., Mundy G.R. Cancer and bone. Endocr. Rev. 19:1998;18-54
4. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T.L., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins H., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176
5. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:1999;304-309
6. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:1998;395-400
7. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319
8. Grimaud E., Rédini F., Heymann D. Osteoprotegerin: a new therapeutic agent for the treatment of bone disease. Drug Discov. Today. 6:2001;1241-1242
9. Good C.R., O'Keefe R.J., Puzas J.E., Schwarz E.M., Rosier R.N. Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J. Surg. Oncol. 79:2002;174-179
10. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., Gouin F., Rédini F., Heymann D. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163:2003;2021-2031
11. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 98:2001;3527-3533
12. Roux S., Meignin V., Quillard J., Meduri G., Guiochon-Mantel A., Fermand J.P., Milgrom E., Mariette X. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br. J. Haematol. 117:2002;86-92
13. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., Findlay D.M., Bardy P., Zannettino A.C. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63:2003;5438-5445
14. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., Brabbs A.C., van Beek E.J., Holen I., Skerry T.M., Dunstan C.R., Russell G.R., Van Camp B., Vanderkerken K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 98:2001;3534-3540
15. Sezer O., Heider U., Jakob C., Eucker J., Possinger K. Human bone marrow myeloma cells express RANKL. J. Clin. Oncol. 20:2002;353-354
16. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., Choi Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11581-11586
17. Giuliani N., Colla S., Sala R., Moroni M., Lazzaretti M., La Monica S., Bonomini S., Hojden M., Sammarelli G., Barillé S., Bataille R., Rizzoli V. Human myeloma cells stimulate the receptor activator of nuclear factor-kappaB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 100:2002;4615-4621
18. Seidel C., Hjertner O., Abildgaard N., Heickendorff L., Hjorth M., Westin J., Nielsen J.S., Hjorth-Hansen H., Waage A., Sundan A., Borset M. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 98:2001;2269-2271
19. Lipton A., Ali S.M., Leitzel K., Chinchilli V., Witters L., Engle L., Holloway D., Bekker P., Dunstan C.R. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res. 8:2002;2306-2310
20. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., Borset M., Sundan A. Osteoprotegerin is bound, internalised and degraded by multiple myeloma cells. Blood. 100:2002;3002-3007
21. Terpos E., Szydlo R., Apperley J.F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., Goldman J.M., Rahemtulla A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 102:2003;1064-1069
22. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T., Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kB ligand on adult T-cell leukemia cells. Blood. 99:2002;634-640
23. Huang L., Cheng Y.Y., Chow L.T.C., Zheng M.H., Kumta S.M. Tumour cells produce receptor activator of NF-kB ligand (RANKL) in skeletal metastases. J. Clin. Pathol. 55:2002;877-878
24. Demers L.M. Bone markers in the management of patients with skeletal metastases. Cancer. 97:2003;874-879
25. Kitazawa S., Kitazawa R. RANK ligand is a prerequesite for cancer-associated osteolytic lesions. J. Pathol. 198:2002;228-236
26. Park H.R., Min S.K., Cho H.D., Kim D.H., Shin H.S., Park Y.E. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci. 18:2003;541-546
27. Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., Zhang X., Lieberman J.R. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res. 21:2003;62-72
28. Lin B.L., Tarnowski C.P., Zhang J., Rohn E., Patel A.H., Morris M.D., Keller E.T. Bone metastatic LNCaP-derived C4-2B prostate cancer cell line mineralises in vitro. Prostate. 47:2001;212-221
29. Brown J.M., Corey E., Lee Z.D., True L.D., Bun T.J., Tondravi M., Vessela R.L. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology. 57:2001;611-616
30. Holen I., Croucher P.I., Hamdy F.C., Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62:2002;1619-1623
31. Jung K., Lein M., von Hösslin K., Brux B., Schnorr D., Loening S.A., Sinha P. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin. Chem. 47:2001;2061-2063
32. Jung K., Stephan C., Semjonow A., Lein M., Schnorr D., Loening A. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B Ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J. Urol. 170:2003;2302-2305
33. Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63:2003;912-916
34. Atkins G.J., Haynes D.R., Graves S.E., Evdokiou A., Hay S., Bouralexis S., Findlay D.M. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 15:2000;640-649
35. Huang L., Xu J., Wood D.J., Zheng M.H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kB in giant cell tumor of bone. Am. J. Pathol. 156:2000;761-767
36. Miyamoto N., Higuchi Y., Tajima M., Ito M., Tsurudome M., Nishio M., Kawano M., Sudo A., Uchida A., Ito Y. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. J. Orthop. Res. 18:2000;647-654
37. Huang L., Cheng Y.Y., Chow L.T., Zheng M.H., Kumta S.M. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol. Pathol. 56:2003;116-120
38. Goltzman D. Osteolysis and cancer. J. Clin. Invest. 107:2001;1219-1220
39. Chirgwin J.M., Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 10:2000;159-178
40. Chikatsu N., Takeuchi Y., Tamura Y., Fukumoto S., Yano K., Tsuda E., Ogata E., Fujita T. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem. Biophys. Res. Commun. 267:2000;632-637
41. Perez M., Migliaccio S., Taranta A., Festuccia C., Orru L., Brama M., Bologna M., Faraggiana T., Baron R., Teti A. Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. Eur. J. Cancer. 37:2001;629-640
42. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., Gillepsie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:1999;4451-4458
43. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res. 100:2001;18-24
44. Ohshiba T., Miyaura C., Inada M., Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer. 88:2003;1318-1326
45. Fizazi K., Yang J., Peleg S., Sikes C.R., Kreimann E.L., Daliani D., Olive M., Raymond K.A., Janus T.J., Logothetis C.J., Karsenty G., Navone N.M. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 9:2003;2587-2597
46. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., Keller E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107:2001;1235-1244
47. Nagai M., Kyakumoto S., Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun. 269:2000;532-536
48. Michigami T., Ihara-Watanabe M., Yamazaki M., Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61:2001;1637-1644
49. Guise T.A., Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin. Orthop. 415:2003;S32-38
50. Blum B., Moseley J., Miller L., Richelsoph K., Haggard W. Measurement of bone morphogenetic proteins and other growth factors in demineralized bone matrix. Orthopedics. 27:2004;S161-S165
51. Thiéry J.-P., Perdereau B., Gongora R., Gongora G., Mazabraud A. Un modèle experimental d'ostéosarcome chez le rat: II. L'ostéosarcome greffable du rat. Sem. Hôp. Paris. 58:1982;1686-1689
52. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3597-3602
53. Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., Fujise N., Higashio K., Motoyoshi K., Yamamoto M., Nagata N. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone. 23:1998;495-498
54. Capparelli C., Kostenuik P.J., Morony S., Starnes C., Weimann B., Van G., Scully S., Qi M., Lacey D.L., Dunstan C.R. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res. 60:2000;783-787
55. Clohisy D.R., Ramnaraine M.L., Scully S., Qi M., Van G., Tan H.L., Lacey D.L. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J. Orthop. Res. 18:2000;967-976
56. Croucher P.I., Shipman C.M., Van Camp B., Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer. 97:2003;818-824
57. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63:2003;287-289
58. Yonou H., Kanomata N., Goya M., Kamijo T., Yokose T., Hasebe T., Nagai K., Hatano T., Ogawa Y., Ochiai A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 63:2003;2096-2102
59. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., O'keefe P.F., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6:2000;521-528
60. Luger N.M., Honore P., Sabino M.A.C., Schwei M.J., Rogers S.D., Mach D.B., Clohisy D.R., Mantyh P.W. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 61:2001;4038-4047
61. Atkins G.J., Bouralexis S., Haynes D.R., Graves S.E., Geary S.M., Evdokiou A., Zannettino A.C., Hay S., Findlay D.M. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone. 28:2001;370-377
62. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., Harousseau J.M., Lipton A., Mariette X., Williams C.D., Nakanishi A., Holloway D., Martin S.W., Dunstan C.R., Bekker P.J. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 97:2003;887-892
63. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:1998;14363-14367
64. Zhang J., Dai J., Yao Z., Lu Y., Dougall W., Keller E.T. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63:2003;7883-7890
65. Sordillo E.M., Pearse R.N. RANK-Fc: a therapeutic antagonist for RANKL in myeloma. Cancer. 97:2003;802-812
66. Oyajobi B.O., Mundy G.R. Receptor activator of NF-kB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer. 97:2003;813-817
67. Cheng X., Kinosaki M., Takami M., Choi Y., Zhang H., Murali R. Disabling of RANK receptor complex by novel osteoprotegerin like peptidomimetics restores bone loss in-vivo. J. Biol. Chem. 84:2004;274-277